Clinlogix has acquired ikfe CRO GmbH headquartered in Mainz, Germany, expanding its geographic reach in the European market. Clinlogix offers services to support the clinical development of medical devices, pharmaceuticals, biologics and diagnostics, from early feasibility/discovery through first-in-human, feasibility, pivotal and post-market clinical studies.
JeanMarie Markham, chief executive officer of Clinlogix, said, “Our flexible business model focuses on innovation, integration and execution to drive operational excellence and efficiency. It has supported our rapid growth in the U.S., Latin America and now Europe. Ikfe CRO is a high quality acquisition that provides us with the personnel, relationships and infrastructure to bring our unique service mix to clients on a worldwide basis.”
Dr. Marco Grenningloh, Ph.D., chief operating officer and managing director of Clinlogix Europe, said, “This acquisition greatly strengthens our strategic resources, knowledge base and infrastructure in the largest pharmaceutical market in the world. Ikfe CRO was a highly respected regional service provider, and their specialized expertise and in-depth understanding are further enhancing our ability to provide knowledgeable, high quality services to our clients around the globe.”